Inhaled Imatinib Designated Orphan Drug for Pulmonary Arterial Hypertension
AER-901 is an investigational drug-device combination therapy that consists of a nebulized formulation of imatinib and the Fox device, a breath-actuated smart nebulizer.
Pulmonary Hypertension
Midodrine Cuts Recurrent Syncope in Young, Healthy Patients
Absolute risk reduced by 19 percentage points, with number needed to treat to prevent syncope of 5.3
FDA Approves IV Formulation of Uptravi for Pulmonary Arterial Hypertension
The approval was based on data from a single sequence cross-over phase 3 study that evaluated the safety, tolerability and pharmacokinetics of temporarily switching between the tablet and IV formulation.
FDA to Review Dry Powder Inhalation Formulation of Tyvaso
Tyvaso DPI is an investigational drug-device combination therapy consisting of a dry powder formulation of treprostinil.
Case Report: Vitamin C Rapidly Reverses Pulmonary HTN Secondary to Scurvy
Ascorbic acid level testing confirmed severe deficiency (<0.1mg/dL).
Sotatercept Reduces Pulmonary Vascular Resistance in PAH
Decrease in pulmonary vascular resistance at 24 weeks greater with sotatercept versus placebo for pulmonary arterial hypertension
Tyvaso Approved for Pulmonary Hypertension With Interstitial Lung Disease
The sNDA approval is supported by data from the phase 3 INCREASE study that evaluated Tyvaso inhalation solution in 326 adults with PH-ILD.
Remunity Pump for Remodulin Now Available
Remunity Pump is intended for continuous subcutaneous delivery of Remodulin in prefilled cassettes for the treatment of PAH in adults aged ≥22 years.
Pulmonary Hypertension May Increase In-Hospital Mortality in Acute COPD Exacerbations
Pulmonary hypertension is associated with higher in-hospital mortality, morbidity, length of stay, and health care utilization in patients admitted to the hospital with an acute exacerbation of COPD.
Treprostinil Under Review for Pulmonary HTN With Interstitial Lung Disease
The sNDA is supported by data from the multicenter, double-blind, placebo-controlled phase 3 INCREASE study.
